



# Spylidone

## 1. Discovery, producing organism and structure<sup>1-3)</sup>

Spylidone was isolated from the culture broth of *Phoma* sp. FKI-1840 as an inhibitor of lipid droplet accumulation in mouse macrophages. In addition, the structurally related compounds, PF1052 and vermispurin, were isolated together with spylidone.



*Phoma* sp. FKI-1840  
Bar: 50  $\mu\text{m}$




## 2. Physical data (Spylidone)

Colorless oil.  $\text{C}_{26}\text{H}_{39}\text{NO}_4$ ; mol wt 429.59. Sol. in DMSO, MeOH,  $\text{CHCl}_3$ , EtOAc. Insol. in  $\text{H}_2\text{O}$ .

## 3. Biological activity<sup>1,4)</sup>

Inhibitory activity against cholesteryl ester (CE) and triacylglycerol (TG) synthesis of the cytosolic lipid droplet in mouse macrophage was tested. Spylidone inhibited CE synthesis in a dose-dependent manner with an  $\text{IC}_{50}$  value of 42  $\mu\text{M}$ , but showed almost no inhibition of TG synthesis even at 109  $\mu\text{M}$ . Conversely, PF1052 and vermispurin inhibited CE, TG and phospholipid synthesis to similar extents, probably due to their cytotoxic effects on macrophages. Thus, among the three compounds, only spylidone showed selectivity.<sup>1)</sup>



Spylidone inhibited ACAT1 ( $\text{IC}_{50} = 25 \mu\text{M}$ ) and ACAT2 ( $\text{IC}_{50} = 5.0 \mu\text{M}$ ) to similar extent.<sup>4)</sup>

## 4. References

- [888] N. Koyama *et al.*, *J. Antibiot.* **58**, 338-345 (2005)
- A. Takahashi *et al.*, *Jpn. Kokai Tokkyo Koho* JP 08059612 (1996)
- T. Mikawa *et al.*, *Jpn. Kokai Tokkyo Koho* JP 02040328 (1990)
- [955] T. Ohshiro *et al.*, *J. Antibiot.* **60**, 43-51 (2007)